Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Oncology Nurses Who Proactively Manage CAR T-Cell Therapy-Related AEs Can Ensure Their Patients Remain on Treatment

      August 11, 2021
      By Kelly L. Garvin, BSN, RN, OCN
      Video
      Conferences|Annual School of Nursing Oncology

      Proper training can help oncology nurses act as intensivists and quickly identify if their patients are experiencing any CAR T-cell therapy-related adverse events.

      Oncology nurses need adequate training to be able to recognize the signs and symptoms of CAR T-cell therapy-related adverse events (AEs) to ensure their patients can remain on their treatment, according to Kelly L. Garvin, BSN, RN, OCN.

      Garvin, of the H. Lee Moffitt Cancer Center, recently spoke with Oncology Nursing News® and offered insight into how nurses could proactively help their patients manage CAR T-cell therapy-related AEs. Garvin recently presented on the topic at the 5th Annual School of Nursing Oncology.

      Nurses who support patients receiving CAR T-cell treatments, Garvin noted, are specially trained to operate similarly to intensivists, which means they can float between the intensive care floor and the CAR T floor, while nurses from Med-Surg cannot. In addition, nurses who work with patients receiving CAR T treatments need to be able to recognize the early signs of cytokine release syndrome (CRS), neurotoxicity, and ICANS, before the symptoms begin to progress.

      Garvin also noted that nurses should take their patients’ vital signs more often and perform other tasks to be quickly alerted if a patient is experiencing CAR T-cell therapy-related AEs.

      “So, instead of once-a-shift, we (take vital signs) every four hours and do a cranial nerve check every time we go in there. We can look for signs like headaches, aphasia, or confusion,” she said. “We can (also) ask the patient to write out a sentence and see if there are any tremors in their penmanship.”

      Reference

      Garvin KL. CAR-T Therapy Nursing Considerations; Patient Education & Toxicity Management. Presented at: 5th Annual School of Nursing Oncology Live, Interactive Webcast. August 6-August 7, 20201.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Photo of a woman wearing a blazer and a colorful scarf in front of a blue background
      Photo of a woman with red hair and glasses wearing a black blouse and cross necklace in front of a dark blue background
      Photo of a man wearing a suit with a blue tie in front of a dark blue background
      4 experts in this video
      Related Content

      Graphic of malignant B cells

      Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL

      Chris Ryan
      July 30th 2025
      Article

      Adding sonrotoclax to zanubrutinib led to deep and durable response in relapsed or refractory mantle cell lymphoma, according to EHA Congress data.


      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      December 14th 2023
      Podcast

      Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.


      Graphic depicting red blood cells

      Generic Ibrutinib Tablet Given Tentative FDA Approval in CLL/SLL, WM

      Bridget Hoyt
      July 25th 2025
      Article

      A generic version of ibrutinib was granted tentative approval by the FDA for use in CLL and SLL with 17p deletion and Waldenström macroglobulinemia.


      Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

      Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

      Lindsay Fischer
      December 1st 2023
      Podcast

      Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.


      Graphic of a kidney with a tumor

      KIM-1 Biomarker May Be Prognostic of Response, Outcomes in RCC

      Kyle Doherty
      July 21st 2025
      Article

      Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.


      Graphic of a kidney

      Neoantigen Vaccine Shows Promise in Mutated Renal Cell Carcinoma

      Ashling Wahner
      July 18th 2025
      Article

      A personalized neoantigen vaccine may be effective in patients with clear cell renal cell carcinoma, shared David A. Braun, MD, PhD.

      Related Content

      Graphic of malignant B cells

      Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL

      Chris Ryan
      July 30th 2025
      Article

      Adding sonrotoclax to zanubrutinib led to deep and durable response in relapsed or refractory mantle cell lymphoma, according to EHA Congress data.


      The Vitals

      Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

      Lindsay Fischer
      December 14th 2023
      Podcast

      Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.


      Graphic depicting red blood cells

      Generic Ibrutinib Tablet Given Tentative FDA Approval in CLL/SLL, WM

      Bridget Hoyt
      July 25th 2025
      Article

      A generic version of ibrutinib was granted tentative approval by the FDA for use in CLL and SLL with 17p deletion and Waldenström macroglobulinemia.


      Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

      Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

      Lindsay Fischer
      December 1st 2023
      Podcast

      Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.


      Graphic of a kidney with a tumor

      KIM-1 Biomarker May Be Prognostic of Response, Outcomes in RCC

      Kyle Doherty
      July 21st 2025
      Article

      Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.


      Graphic of a kidney

      Neoantigen Vaccine Shows Promise in Mutated Renal Cell Carcinoma

      Ashling Wahner
      July 18th 2025
      Article

      A personalized neoantigen vaccine may be effective in patients with clear cell renal cell carcinoma, shared David A. Braun, MD, PhD.

      Latest Conference Coverage

      Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL

      Q&A: Nursing Considerations From Immune Cell Effector Therapy Experts

      Proactive Rash Management Vital for PI3K, AKT Inhibition in Breast Cancer

      Understanding How On-Target and Off-Target ADC Toxicities Work

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.